ATE530667T1 - Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit - Google Patents

Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit

Info

Publication number
ATE530667T1
ATE530667T1 AT06763326T AT06763326T ATE530667T1 AT E530667 T1 ATE530667 T1 AT E530667T1 AT 06763326 T AT06763326 T AT 06763326T AT 06763326 T AT06763326 T AT 06763326T AT E530667 T1 ATE530667 T1 AT E530667T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
kcnn3
diagnostic
therapeutic target
Prior art date
Application number
AT06763326T
Other languages
English (en)
Inventor
Johannes Pohlner
Der Kammer Heinz Von
Original Assignee
Evotec Neurosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh filed Critical Evotec Neurosciences Gmbh
Application granted granted Critical
Publication of ATE530667T1 publication Critical patent/ATE530667T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
AT06763326T 2005-05-27 2006-05-29 Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit ATE530667T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68507205P 2005-05-27 2005-05-27
EP05104552 2005-05-27
PCT/EP2006/062667 WO2006125830A2 (en) 2005-05-27 2006-05-29 Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE530667T1 true ATE530667T1 (de) 2011-11-15

Family

ID=35457791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06763326T ATE530667T1 (de) 2005-05-27 2006-05-29 Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit

Country Status (5)

Country Link
US (2) US20090172827A1 (de)
EP (1) EP1888783B1 (de)
JP (1) JP2008545402A (de)
AT (1) ATE530667T1 (de)
WO (1) WO2006125830A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗-Aβ球聚体抗体,其抗原结合部分,相应的杂交瘤、核酸、载体、宿主细胞,生产所述抗体的方法,包含所述抗体的组合物,所述抗体的应用以及使用所述抗体的方法
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
FR2929292A1 (fr) * 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
HUP0900431A2 (en) * 2009-07-10 2011-01-28 Cryo Innovation Kft Sample imaging system and pocedure for transmitting imager of cells or tissues located in breeder space towards a data processing device
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
US9523673B2 (en) 2011-10-04 2016-12-20 Psychnostics, Llc Methods for diagnosing and identifying modulators of membrane potentials in bipolar disorder and attention deficit hyperactivity disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4438391C2 (de) 1994-10-27 1997-07-03 Evotec Biosystems Gmbh Vorrichtung zur Bestimmung stoffspezifischer Parameter eines oder weniger Moleküle mittels Korrelations-Spektroskopie
DE19709348C2 (de) 1996-05-29 1999-07-01 Schubert Walter Dr Md Automatisches Multi-Epitop-Ligand-Kartierungsverfahren
EP0836090A1 (de) 1996-10-12 1998-04-15 Evotec BioSystems GmbH Probenanalyseverfahren durch Bestimmung der spezifischen Helligkeitsverteilung von Teilchen
DE19649048C1 (de) 1996-11-27 1998-04-09 Evotec Biosystems Gmbh Verfahren zur Unterscheidung oder Erfassung von Partikeln in einer Probe durch Identifizierung von Signalabschnitten zeitaufgelöster, optischer Rohsignale aus der Probe auf Basis von Einzelphotonendetektion
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
EP0945718A1 (de) 1998-03-21 1999-09-29 Evotec BioSystems AG Ein Verfahren zur Probencharakterisierung durch Bestimmung einer Funktion mindestens einer spezifischen Eigenschaft von Einheiten der Probe
WO1999034195A1 (de) 1997-12-23 1999-07-08 Evotec Biosystems Ag Verfahren zum nachweis von reaktionen mittels koinzidenzanalyse
WO2000052451A1 (en) 1999-03-03 2000-09-08 Evotec Analytical Systems Gmbh Homogeneous fluorescence assay
ATE235045T1 (de) 1999-04-29 2003-04-15 Evotec Ag Verfahren zur erfassung von fluoreszierenden molekülen oder anderen teilchen mittels erzeugenden funktionen
US6690463B2 (en) 2000-02-10 2004-02-10 Evotec Biosystems Ag Fluorescence intensity and lifetime distribution analysis
ATE264499T1 (de) 2000-02-10 2004-04-15 Evotec Ag Fluoreszenzintensitätsanalyse unter verwendung einer vielzahl von verteilungen: konkurrierende bestimmung von diffusionszeiten und molekularer helligkeit
DE10030798A1 (de) 2000-06-29 2002-01-10 Evotec Analytical Sys Gmbh Kompetitives Assay-Verfahren
WO2004020665A2 (en) 2002-08-28 2004-03-11 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
US20050010967A1 (en) * 2003-02-28 2005-01-13 The Regents Of The University Of California SK3-1B GFP transgenic mouse model for spinocerebellar ataxia and hyperexcitable behavior

Also Published As

Publication number Publication date
WO2006125830A2 (en) 2006-11-30
EP1888783B1 (de) 2011-10-26
WO2006125830A3 (en) 2007-02-15
US20110010780A1 (en) 2011-01-13
JP2008545402A (ja) 2008-12-18
EP1888783A2 (de) 2008-02-20
US20090172827A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
ATE461941T1 (de) Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
HK1117083A1 (en) Compositions and methods for treatment of eye disorders
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
EP1408333A3 (de) Diagnose und behandlung von alzheimer's krankheit
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
ATE495269T1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
ATE534751T1 (de) Verwendung von prkx zur diagnose und therapie von alzheimer krankheit
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
ATE458834T1 (de) Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
WO2005030947A3 (en) Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
ATE464567T1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
WO2006131562A3 (en) Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases
WO2005101014A3 (en) Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
WO2004020665A3 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
ATE316657T1 (de) Diagnostische und therapeutische verwendung des caps
WO2006008294A3 (en) Diagnostic and therapeutic use of slim3 for neurodegenerative diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties